Lidocaine hydrochloride

製品コードS4667 バッチS466701

印刷

化学情報

Chemical Structure Synonyms Lidocaine HCL, Lidothesin, Lignocaine hydrochloride, Xyloneural Storage
(From the date of receipt)		 3 years -20°C powder
1 years -80°C in solvent
化学式

C14H22N2O.HCl
分子量 270.8 CAS No. 73-78-9
Solubility (25°C)* 体外 DMSO 54 mg/mL (199.4 mM)
Water 54 mg/mL (199.4 mM)
Ethanol 54 mg/mL (199.4 mM)
* <1 mg/ml means slightly soluble or insoluble.
* Please note that Selleck tests the solubility of all compounds in-house, and the actual solubility may differ slightly from published values. This is normal and is due to slight batch-to-batch variations.

溶剤液（一定の濃度）を調合する

生物活性

製品説明 Lidocaine hydrochloride (Lidothesin, Lignocaine, Xyloneural) is an inhibitor of epidermal growth factor receptor (EGFR) and has antiproliferative effect on human tongue cancer cells. Lidocaine hydrochloride is a local anesthetic and cardiac depressant used as an antiarrhythmia agent.
in vitro Lidocaine above 1.25 g/l reduces cellular viability and triggers apoptosis in HCE cells in a time- and dose-dependent manner. Lidocaine-induced apoptosis is caspase dependent and may be related to mitochondrial pathway[1]. Lidocaine, at the level of tissue concentration under topical or local administration, also has a direct inhibitory effect on the activity of epidermal growth factor receptor (EGFR), which is a potential target for antiproliferation in cancer cells[3].
in vivo Intravenous administration of the local anaesthetic lidocaine has been used to treat neuropathic pain for several decades and significantly improves postoperative pain associated with complex spine surgery and cholecystectomy. It is well established that lidocaine used for regional anaesthesia blocks impulses in peripheral nerves by inhibiting voltage-gated sodium (Na+) channels. Intravenous lidocaine has an analgesic effect on mechanical noxious response, decreases the spinal noxious response induced by peripheral pinch stimuli and the frequency of spontaneous excitatory postsynaptic currents(EPSCs) without changing their amplitude. It has no effect on spontaneous inhibitory postsynaptic currents and produces an outward current in SG neurons[2].

プロトコル(参考用のみ)

細胞アッセイ 細胞株 Human Corneal Endothelial Cells
濃度 0.15625–10.0 g/l
反応時間 4-28 hr
実験の流れ Cells at logarithmic phase are treated with lidocaine hydrochloride at concentrations (w/v) from 10 to 0.15625 g/l in step dilutions. HCE cells without lidocaine treatment are used as controls. The morphology and growing status of the cells are monitored every 4 hr.
動物実験 動物モデル Male Wistar rats
投薬量 1, 3, 10 mg/kg
投与方法 i.v.

Selleckの高級品が、幾つかの出版された研究調査結果（以下を含む）で使われた：

Lidocaine suppresses the malignant behavior of gastric cancer cells via the c-Met/c-Src pathway [ Exp Ther Med, 2021, 21(5):424] PubMed: 33747163

長期の保管のために-20°Cの下で製品を保ってください。

人間や獣医の診断であるか治療的な使用のためにでない。

各々の製品のための特定の保管と取扱い情報は、製品データシートの上で示されます。大部分のSelleck製品は、推薦された状況の下で安定です。製品は、推薦された保管温度と異なる温度で、時々出荷されます。長期の保管のために必要とされてそれと異なる温度で、多くの製品は、短期もので安定です。品質を維持するが、夜通しの積荷のために最も経済的な貯蔵状況を用いてあなたの送料を保存する状況の下に、製品が出荷されることを、我々は確実とします。製品の受領と同時に、製品データシートの上で貯蔵推薦に従ってください。